FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Ross Camidge, a leading thoracic medical oncologist from the University of Colorado, to discuss the recent approval of telisotuzumab-vedotin (Teliso-V) for metastatic non-small cell lung cancer (NSCLC) with C-met overexpression, based on the LUMINOSITY trial.

Join us as we explore:
• The mechanism of action of telisotuzumab and its role as an antibody-drug conjugate.
• The prevalence of C-met overexpression in NSCLC and its implications for testing and treatment.
• Key findings from the Luminosity trial, including response rates and study design.
• The importance of C-met testing in clinical practice.
• Management of side effects associated with telisotuzumab, particularly peripheral neuropathy.

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

This episode is packed with valuable insights for oncologists and healthcare professionals navigating the evolving landscape of lung cancer treatment. Don't miss out on this informative discussion!